These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
444 related articles for article (PubMed ID: 19816150)
1. Nodal diffuse large B-cell lymphomas in children and adolescents: immunohistochemical expression patterns and c-MYC translocation in relation to clinical outcome. Gualco G; Weiss LM; Harrington WJ; Bacchi CE Am J Surg Pathol; 2009 Dec; 33(12):1815-22. PubMed ID: 19816150 [TBL] [Abstract][Full Text] [Related]
2. BCL2 positive and BCL6 negative diffuse large B cell lymphoma patients benefit from R-CHOP therapy irrespective of germinal and non germinal center B cell like subtypes. Jovanovic MP; Mihaljevic B; Jakovic L; Martinovic VC; Fekete MD; Andjelic B; Antic D; Bogdanovic A; Boricic N; Terzic T; Jelicic J; Milenkovic S J BUON; 2015; 20(3):820-8. PubMed ID: 26214636 [TBL] [Abstract][Full Text] [Related]
3. Colorectal diffuse large B-cell lymphoma: molecular subclassification and prognostic significance of immunoglobulin gene translocation. Hori Y; Yamamoto H; Nozaki Y; Torisu T; Fujiwara M; Taguchi K; Nishiyama K; Nakamura S; Kitazono T; Oda Y Hum Pathol; 2020 Feb; 96():67-78. PubMed ID: 31734190 [TBL] [Abstract][Full Text] [Related]
4. B-cell lymphomas with concurrent IGH-BCL2 and MYC rearrangements are aggressive neoplasms with clinical and pathologic features distinct from Burkitt lymphoma and diffuse large B-cell lymphoma. Snuderl M; Kolman OK; Chen YB; Hsu JJ; Ackerman AM; Dal Cin P; Ferry JA; Harris NL; Hasserjian RP; Zukerberg LR; Abramson JS; Hochberg EP; Lee H; Lee AI; Toomey CE; Sohani AR Am J Surg Pathol; 2010 Mar; 34(3):327-40. PubMed ID: 20118770 [TBL] [Abstract][Full Text] [Related]
5. Prognostic impact of germinal center-associated proteins and chromosomal breakpoints in poor-risk diffuse large B-cell lymphoma. van Imhoff GW; Boerma EJ; van der Holt B; Schuuring E; Verdonck LF; Kluin-Nelemans HC; Kluin PM J Clin Oncol; 2006 Sep; 24(25):4135-42. PubMed ID: 16943530 [TBL] [Abstract][Full Text] [Related]
6. Clinical significance of 'double-hit' and 'double-expression' lymphomas. Ma Z; Niu J; Cao Y; Pang X; Cui W; Zhang W; Li X J Clin Pathol; 2020 Mar; 73(3):126-138. PubMed ID: 31615842 [TBL] [Abstract][Full Text] [Related]
7. Role of immunohistochemistry in the era of genetic testing in MYC-positive aggressive B-cell lymphomas: a study of 209 cases. Agarwal R; Lade S; Liew D; Rogers TM; Byrne D; Feleppa F; Juneja S; Westerman DA J Clin Pathol; 2016 Mar; 69(3):266-70. PubMed ID: 26307073 [TBL] [Abstract][Full Text] [Related]
8. [Survival of patients with primary central nervous system diffuse large B-cell lymphoma: impact of gene aberrations and protein overexpression of bcl-2 and C-MYC, and selection of chemotherapy regimens]. Yin WJ; Zhu X; Yang HY; Sun WY; Wu MJ Zhonghua Bing Li Xue Za Zhi; 2018 Jan; 47(1):32-38. PubMed ID: 29325248 [No Abstract] [Full Text] [Related]
9. CD30 expression and its correlation with MYC and BCL2 in de novo diffuse large B-cell lymphoma. Gong QX; Wang Z; Liu C; Li X; Lu TX; Liang JH; Xu W; Li JY; Zhang ZH J Clin Pathol; 2018 Sep; 71(9):795-801. PubMed ID: 29666157 [TBL] [Abstract][Full Text] [Related]
10. Clinical Significance of Ting CY; Chang KM; Kuan JW; Sathar J; Chew LP; Wong OJ; Yusuf Y; Wong L; Samsudin AT; Pana MNBM; Lee SK; Gopal NSR; Puri R; Ong TC; Bahari SK; Goh AS; Teoh CS Int J Med Sci; 2019; 16(4):556-566. PubMed ID: 31171907 [No Abstract] [Full Text] [Related]
11. Triple-hit B-cell Lymphoma With MYC, BCL2, and BCL6 Translocations/Rearrangements: Clinicopathologic Features of 11 Cases. Wang W; Hu S; Lu X; Young KH; Medeiros LJ Am J Surg Pathol; 2015 Aug; 39(8):1132-9. PubMed ID: 25828391 [TBL] [Abstract][Full Text] [Related]
12. Coexpression of MYC and BCL-2 predicts prognosis in primary gastrointestinal diffuse large B-cell lymphoma. Xia B; Zhang L; Guo SQ; Li XW; Qu FL; Zhao HF; Zhang LY; Sun BC; You J; Zhang YZ World J Gastroenterol; 2015 Feb; 21(8):2433-42. PubMed ID: 25741152 [TBL] [Abstract][Full Text] [Related]
13. MYC single-hit large B-cell lymphoma: clinicopathologic difference from MYC-negative large B-cell lymphoma and MYC double-hit/triple-hit lymphoma. Cho YA; Hyeon J; Lee H; Cho J; Kim SJ; Kim WS; Ko YH Hum Pathol; 2021 Jul; 113():9-19. PubMed ID: 33771538 [TBL] [Abstract][Full Text] [Related]
14. T-cell leukemia 1 expression in nodal Epstein-Barr virus-negative diffuse large B-cell lymphoma and primary mediastinal B-cell lymphoma. Gualco G; Weiss LM; Barber GN; Bacchi CE Hum Pathol; 2010 Sep; 41(9):1238-44. PubMed ID: 20382409 [TBL] [Abstract][Full Text] [Related]
15. C-MYC overexpression predicts aggressive transformation and a poor outcome in mucosa-associated lymphoid tissue lymphomas. Huang W; Guo L; Liu H; Zheng B; Ying J; Lv N Int J Clin Exp Pathol; 2014; 7(9):5634-44. PubMed ID: 25337204 [TBL] [Abstract][Full Text] [Related]
16. AIDS and non-AIDS diffuse large B-cell lymphomas express different antigen profiles. Madan R; Gormley R; Dulau A; Xu D; Walsh D; Ramesh KH; Cannizaro L; Tamas EF; Kumar P; Sparano J; LeValley A; Xue X; Bhattacharyya PK; Ioachim HL; Ratech H Mod Pathol; 2006 Mar; 19(3):438-46. PubMed ID: 16444194 [TBL] [Abstract][Full Text] [Related]
17. Clinical Impact of the Cell-of-Origin Classification and the MYC/ BCL2 Dual Expresser Status in Diffuse Large B-Cell Lymphoma Treated Within Prospective Clinical Trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group. Staiger AM; Ziepert M; Horn H; Scott DW; Barth TFE; Bernd HW; Feller AC; Klapper W; Szczepanowski M; Hummel M; Stein H; Lenze D; Hansmann ML; Hartmann S; Möller P; Cogliatti S; Lenz G; Trümper L; Löffler M; Schmitz N; Pfreundschuh M; Rosenwald A; Ott G; J Clin Oncol; 2017 Aug; 35(22):2515-2526. PubMed ID: 28525305 [TBL] [Abstract][Full Text] [Related]
18. MYC expression in concert with BCL2 and BCL6 expression predicts outcome in Chinese patients with diffuse large B-cell lymphoma, not otherwise specified. Yan LX; Liu YH; Luo DL; Zhang F; Cheng Y; Luo XL; Xu J; Cheng J; Zhuang HG PLoS One; 2014; 9(8):e104068. PubMed ID: 25090026 [TBL] [Abstract][Full Text] [Related]
19. EZH2 overexpression in primary gastrointestinal diffuse large B-cell lymphoma and its association with the clinicopathological features. Liu Y; Yu K; Li M; Zeng K; Wei J; Li X; Liu Y; Zhao D; Fan L; Yu Z; Wang Y; Li Z; Zhang W; Bai Q; Yan Q; Guo Y; Wang Z; Guo S Hum Pathol; 2017 Jun; 64():213-221. PubMed ID: 28438623 [TBL] [Abstract][Full Text] [Related]
20. B-cell lymphomas with MYC/8q24 rearrangements and IGH@BCL2/t(14;18)(q32;q21): an aggressive disease with heterogeneous histology, germinal center B-cell immunophenotype and poor outcome. Li S; Lin P; Fayad LE; Lennon PA; Miranda RN; Yin CC; Lin E; Medeiros LJ Mod Pathol; 2012 Jan; 25(1):145-56. PubMed ID: 22002575 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]